Clinical trials: Pancreatic Metastatic Cancer
Pancreatic Cancer, Advanced or Metastatic, BRCA1/2 Mutation
Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer
This study will compare two different regimens for patients with BRCA1/2 or PALB2 mutated metastatic pancreatic cancer after progression on first-line FOLFIRINOX.
- Conditions
- Pancreatic Cancer, Advanced or Metastatic, BRCA1/2 Mutation, PALB2 Gene Mutation
- Trial name
- PLATINUM-CAN (NCT06783140)
- Testing
- Nab paclitaxel, Gemcitabine, Cisplatin
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1…
- Trial name
- NCT05431270
- Testing
- Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Phanes Therapeutics
Pancreatic Adenocarcinoma, Chemotherapy Effect
The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer
Pancreatic cancer is a very poor prognosis and has a high mortality rate. The clinical results have improved somewhat with the combination therapy of chemotherapy as the first-line treatment.
- Trial name
- NCT03401827
- Testing
- Chemotherapy (Gemcitabine + nab-paclitaxel)
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Seoul National University Hospital
Neoplasms, Pancreatic Neoplasms
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Background: LMB-100 is a man-made protein designed to kill cancer cells. LMB-100 targets a cancer marker called mesothelin. Mesothelin is found on the surface of many different tumors, including pancreatic cancer, but is made by…
- Trial name
- NCT02810418
- Testing
- LMB-100, Nab-Paclitaxel, Mesothelin Expression
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Pathology, Head and Neck Cancer (H&N)
FAPI PET Imaging - An Exploratory Study
This study is testing a new imaging tracer called [18F]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions…
- Conditions
- Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis
- Trial name
- FAPIPET (NCT07705074)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 5 sites in Switzerland
- Volunteers
- 770 people
- Sponsor
- Martin Huellner
Disseminated Pancreatic Cancer
Surgery for Liver Metastases From PDAC
Dissemination from pancreatic ductal adenocarcinoma (PDAC) occurs in clinical practice either in the form of recurrence after initial treatment with curative intent resection (metachronous) or more frequently prevails already at…
- Trial name
- ScanPan1 (NCT05271110)
- Testing
- Liver resection (ablation)
- Where
- Sweden
- Volunteers
- 64 people
- Sponsor
- Linkoeping University
Pancreatic Ductal Adenocarcinoma (PDAC)
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
This is a Phase 1b trial evaluating the combination of Fostamatinib, a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura (ITP), with the standard of care chemotherapy agents gemcitabine…
- Trial name
- NCT06639724
- Testing
- Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Diego
Pancreatic Cancer
Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
This is a study in which pancreatic cancer patients receive a combination therapy with CART-meso cells and CART19 cells administered at 3 days after one dose of cyclophosphamide.
- Trial name
- NCT02465983
- Testing
- CART-meso-19 T cells, Cyclophosphamide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Pennsylvania
Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 Combined with Chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma…
- Trial name
- NCT07235202
- Testing
- MR001, Irinotecan Liposome Injection combined with 5-FU/LV, Nab-paclitaxel
- Where
- 4 sites in China
- Volunteers
- 45 people
- Sponsor
- Shenzhen Majory Biotechnology Co., Ltd.
Pancreatic Cancer
A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
The purpose of this study is to determine whether the combination of MM-141 plus nab-paclitaxel and gemcitabine is more effective than nab-paclitaxel and gemcitabine alone based on Progression Free Survival (PFS) in front-line…
- Trial name
- CARRIE (NCT02399137)
- Testing
- MM-141, Gemcitabine, Nab-Paclitaxel
- Where
- 66 sites in United States, Canada and 4 more
- Volunteers
- 88 people
- Sponsor
- Merrimack Pharmaceuticals
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy
The purpose of this study is to evaluate the safety and efficacy of an investigational B7-H3 antibody drug-conjugate administered as monotherapy, compared with standard of care (SOC) chemotherapy in metastatic pancreatic cancer…
- Trial name
- NCT07803783
- Testing
- Tambotatug pelitecan, Liposomal irinotecan, 5 Fluorouracil
- Where
- China
- Volunteers
- 320 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Metastatic Pancreatic Adenocarcinoma
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic reovirus in combination with gemcitabine is effective and safe in the treatment of patients with advanced pancreatic…
- Trial name
- NCT00998322
- Testing
- REOLYSIN, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Oncolytics Biotech
Carcinoma, Hepatocellular, Pancreatic Cancer Metastatic
A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
The purpose of this study is to collect the date on the safety and potential effectiveness of CART cells combined with interventional therapy in patients with advanced liver malignancy.
- Conditions
- Carcinoma, Hepatocellular, Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic
- Trial name
- NCT02959151
- Testing
- CAR-T cell
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai GeneChem Co., Ltd.
Pancreatic Adenocarcinoma Metastatic
Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma
The present project aims to elucidate the metabolic interactions within the tumor microenvironment of pancreatic adenocarcinoma, both in the primary tumor and in hepatic and pulmonary metastatic sites, as well as in circulating…
- Trial name
- NCT07664891
- Testing
- Biopsy collection, Blood collection
- Where
- France
- Volunteers
- 64 people
- Sponsor
- Institut Paoli-Calmettes
Adebrelimab (SHR-1316), Decitabine
Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer
Pancreatic cancer is a kind of digestive system tumor with extremely high malignancy and poor prognosis. Although the trend of benefit from immunotherapy in combination with chemotherapy is currently reflected in several…
- Conditions
- Adebrelimab (SHR-1316), Decitabine, Metastatic Pancreatic Cancer
- Trial name
- NCT06454448
- Testing
- Adebrelimab;decitabine;
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Neuroendocrine Tumors, Pancreatic Neoplasms
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
The purpose of this study is to determine the safety and the efficacy of the combination of the drugs TH-302 and sunitinib in metastatic neuroendocrine tumours.
- Trial name
- NCT02402062
- Testing
- TH-302 + Sunitinib
- Where
- 10 sites in Spain
- Volunteers
- 17 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Pancreatic Cancer, Pancreas Adenocarcinoma
A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer
Chemotherapy regimens for pancreatic cancer can now stabilize a patient's cancer and/or place some patients in remission or partial remission.
- Conditions
- Pancreatic Cancer, Pancreas Adenocarcinoma, Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
- Trial name
- NCT03331562
- Testing
- Pembrolizumab, paricalcitol
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Translational Genomics Research Institute
Pancreatic Cancer
ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study
A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic.
- Trial name
- PanC-ASAP (NCT04431258)
- Testing
- ABTL0812, Folfirinox
- Where
- 24 sites in United States, France and 2 more
- Volunteers
- 150 people
- Sponsor
- Ability Pharmaceuticals SL
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.